Rapamycin Cannot Reduce Seizure Susceptibility in Infantile Rats with Malformations of Cortical Development Lacking mTORC1 Activation.
Malformations of cortical development (MCD)
Methylazoxymethanol (MAM)
N-methyl-D-aspartate (NMDA)
Rapamycin
mTOR
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
25
04
2022
accepted:
04
09
2022
pubmed:
5
10
2022
medline:
2
11
2022
entrez:
4
10
2022
Statut:
ppublish
Résumé
The mechanistic target of the rapamycin (mTOR) pathway is involved in cortical development. However, the efficacy of mTOR inhibitors in malformations of cortical dysplasia (MCD) outside of the tuberous sclerosis complex is unknown. We selected the MCD rat model with prenatal MAM exposure to test the efficacy of mTOR inhibitors in MCDs. We explored the early cortical changes of mTOR pathway protein expression in rats aged P15. We also monitored the early treatment effect of the mTOR inhibitor, rapamycin, on N-methyl-D-aspartate (NMDA)-induced spasms at P15 and their behavior in the juvenile stage. In vivo MR spectroscopy was performed after rapamycin treatment and compared with vehicle controls. There was no difference in mTORC1 pathway protein expression between MAM-exposed MCD rats and controls at P15, and prolonged treatment of rapamycin had no impact on NMDA-induced spasms despite poor weight gain. Prenatal MAM-exposed juvenile rats treated with rapamycin showed increased social approaching and freezing behavior during habituation. MR spectroscopy showed altered neurometabolites, including Gln, Glu+Gln, Tau, and Cr. Despite behavioral changes and in vivo neurometabolic alteration with early prolonged rapamycin treatment, rapamycin had no effect on spasms susceptibility in prenatal MAM-exposed infantile rats with MCD without mTORC1 activation. For MAM-exposed MCD rats without mTORC1 activation, treatment options outside of mTOR pathway inhibitors should be explored.
Identifiants
pubmed: 36194361
doi: 10.1007/s12035-022-03033-9
pii: 10.1007/s12035-022-03033-9
doi:
Substances chimiques
Sirolimus
W36ZG6FT64
Mechanistic Target of Rapamycin Complex 1
EC 2.7.11.1
N-Methylaspartate
6384-92-5
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7439-7449Subventions
Organisme : Ministry of Education
ID : NRF-2021R1A2C100447111
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Iffland PH, Crino PB (2017) Focal cortical dysplasia: gene mutations, cell signaling, and therapeutic implications. Annu Rev Pathol 12:547–571. https://doi.org/10.1146/annurev-pathol-052016-100138
doi: 10.1146/annurev-pathol-052016-100138
pubmed: 28135561
Crino PB (2019) Mechanistic target of rapamycin (mTOR) signaling in status epilepticus. Epilepsy Behav 101(Pt B):106550. https://doi.org/10.1016/j.yebeh.2019.106550
doi: 10.1016/j.yebeh.2019.106550
pubmed: 31732331
Crino PB (2016) The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol 12(7):379–392. https://doi.org/10.1038/nrneurol.2016.81
doi: 10.1038/nrneurol.2016.81
pubmed: 27340022
Griffith JL, Wong M (2018) The mTOR pathway in treatment of epilepsy: a clinical update. Future Neurol 13(2):49–58. https://doi.org/10.2217/fnl-2018-0001
doi: 10.2217/fnl-2018-0001
pubmed: 30505235
pmcid: 6261508
Weston MC, Chen H, Swann JW (2012) Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission. J Neurosci 32(33):11441–11452. https://doi.org/10.1523/JNEUROSCI.1283-12.2012
doi: 10.1523/JNEUROSCI.1283-12.2012
pubmed: 22895726
pmcid: 3432956
Buffington SA, Huang W, Costa-Mattioli M (2014) Translational control in synaptic plasticity and cognitive dysfunction. Annu Rev Neurosci 37(1):17–38. https://doi.org/10.1146/annurev-neuro-071013-014100
doi: 10.1146/annurev-neuro-071013-014100
pubmed: 25032491
pmcid: 4721605
Huang X, Zhang H, Yang J, Wu J, McMahon J, Lin Y, Cao Z, Gruenthal M et al (2010) Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis 40(1):193–199. https://doi.org/10.1016/j.nbd.2010.05.024
doi: 10.1016/j.nbd.2010.05.024
pubmed: 20566381
pmcid: 2926303
Zeng L-H, Rensing NR, Wong M (2009) The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29(21):6964–6972. https://doi.org/10.1523/jneurosci.0066-09.2009
doi: 10.1523/jneurosci.0066-09.2009
pubmed: 19474323
pmcid: 2727061
Chachua T, Poon KL, Yum MS, Nesheiwat L, DeSantis K, Veliskova J, Velisek L (2012) Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats. Epilepsia 53(11):2015–2025. https://doi.org/10.1111/j.1528-1167.2012.03674.x
doi: 10.1111/j.1528-1167.2012.03674.x
pubmed: 23016669
pmcid: 3496841
Chevassus-Au-Louis N, Congar P, Represa A, Ben-Ari Y, Gaiarsa JL (1998) Neuronal migration disorders: heterotopic neocortical neurons in CA1 provide a bridge between the hippocampus and the neocortex. Proc Natl Acad Sci U S A 95(17):10263–10268
doi: 10.1073/pnas.95.17.10263
pubmed: 9707635
pmcid: 21496
Germano IM, Sperber EF (1997) Increased seizure susceptibility in adult rats with neuronal migration disorders. Brain Res 777(1-2):219–222
doi: 10.1016/S0006-8993(97)01022-6
pubmed: 9449431
Paredes M, Pleasure SJ, Baraban SC (2006) Embryonic and early postnatal abnormalities contributing to the development of hippocampal malformations in a rodent model of dysplasia. J Comp Neurol 495(1):133–148. https://doi.org/10.1002/cne.20871
doi: 10.1002/cne.20871
pubmed: 16432901
pmcid: 2827607
Colacitti C, Sancini G, DeBiasi S, Franceschetti S, Caputi A, Frassoni C, Cattabeni F, Avanzini G et al (1999) Prenatal methylazoxymethanol treatment in rats produces brain abnormalities with morphological similarities to human developmental brain dysgeneses. J Neuropathol Exp Neurol 58(1):92–106
doi: 10.1097/00005072-199901000-00010
pubmed: 10068317
Crino PB (2015) Focal cortical dysplasia. Semin Neurol 35(3):201–208. https://doi.org/10.1055/s-0035-1552617
doi: 10.1055/s-0035-1552617
pubmed: 26060899
pmcid: 6413691
Choi BH, Lapham LW, Amin-Zaki L, Saleem T (1978) Abnormal neuronal migration, deranged cerebral cortical organization, and diffuse white matter astrocytosis of human fetal brain: a major effect of methylmercury poisoning in utero. J Neuropathol Exp Neurol 37(6):719–733. https://doi.org/10.1097/00005072-197811000-00001
doi: 10.1097/00005072-197811000-00001
pubmed: 739273
Lombroso CT (2000) Can early postnatal closed head injury induce cortical dysplasia. Epilepsia 41(2):245–253. https://doi.org/10.1111/j.1528-1157.2000.tb00148.x
doi: 10.1111/j.1528-1157.2000.tb00148.x
pubmed: 10691125
Lee M, Kim EJ, Woo DC, Shim WH, Yum MS (2020) In vivo MRI successfully reveals the malformation of cortical development in infant rats. Front Neurosci 14:510. https://doi.org/10.3389/fnins.2020.00510
doi: 10.3389/fnins.2020.00510
pubmed: 32508585
pmcid: 7251149
Kim EH, Yum MS, Lee M, Kim EJ, Shim WH, Ko TS (2017) A new rat model of epileptic spasms based on methylazoxymethanol-induced malformations of cortical development. Front Neurol 8:271. https://doi.org/10.3389/fneur.2017.00271
doi: 10.3389/fneur.2017.00271
pubmed: 28659857
pmcid: 5466970
Yum MS, Lee M, Ko TS, Velisek L (2014) A potential effect of ganaxolone in an animal model of infantile spasms. Epilepsy Res 108(9):1492–1500. https://doi.org/10.1016/j.eplepsyres.2014.08.015
doi: 10.1016/j.eplepsyres.2014.08.015
pubmed: 25219352
Goosens KA, Maren S (2001) Contextual and auditory fear conditioning are mediated by the lateral, basal, and central amygdaloid nuclei in rats. Learn Mem 8(3):148–155. https://doi.org/10.1101/lm.37601
doi: 10.1101/lm.37601
pubmed: 11390634
pmcid: 311374
Marsan E, Baulac S (2018) Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy. Neuropathol Appl Neurobiol 44(1):6–17. https://doi.org/10.1111/nan.12463
doi: 10.1111/nan.12463
pubmed: 29359340
Majolo F, Marinowic DR, Machado DC, Da Costa JC (2018) MTOR pathway in focal cortical dysplasia type 2: what do we know? Epilepsy Behav 85:157–163. https://doi.org/10.1016/j.yebeh.2018.05.014
doi: 10.1016/j.yebeh.2018.05.014
pubmed: 29945038
Yao K, Duan Z, Zhou J, Li L, Zhai F, Dong Y, Wang X, Ma Z et al (2016) Clinical and immunohistochemical characteristics of type II and type I focal cortical dysplasia. Oncotarget 7(47):76415–76422. https://doi.org/10.18632/oncotarget.13001
doi: 10.18632/oncotarget.13001
pubmed: 27811355
pmcid: 5363519
Jansen LA, Mirzaa GM, Ishak GE, O'Roak BJ, Hiatt JB, Roden WH, Gunter SA, Christian SL et al (2015) PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. Brain 138(Pt 6):1613–1628. https://doi.org/10.1093/brain/awv045
doi: 10.1093/brain/awv045
pubmed: 25722288
pmcid: 4614119
Kumari K, Sharma MC, Kakkar A, Malgulwar PB, Pathak P, Suri V, Sarkar C, Chandra SP et al (2020) mTOR pathway activation in focal cortical dysplasia. Ann Diagn Pathol 46:151523. https://doi.org/10.1016/j.anndiagpath.2020.151523
doi: 10.1016/j.anndiagpath.2020.151523
pubmed: 32325422
Carnero A, Paramio JM (2014) The PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol 4. https://doi.org/10.3389/fonc.2014.00252
Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20(14):5010–5018. https://doi.org/10.1128/MCB.20.14.5010-5018.2000
doi: 10.1128/MCB.20.14.5010-5018.2000
pubmed: 10866658
pmcid: 85951
Kielbinski M, Setkowicz Z, Gzielo K, Janeczko K (2018) Profiles of gene expression in the hippocampal formation of rats with experimentally-induced brain dysplasia. Dev Neurobiol 78(7):718–735. https://doi.org/10.1002/dneu.22595
doi: 10.1002/dneu.22595
pubmed: 29663692
Jesus-Ribeiro J, Pires LM, Melo JD, Ribeiro IP, Rebelo O, Sales F, Freire A, Melo JB (2020) Genomic and epigenetic advances in focal cortical dysplasia types I and II: a scoping review. Front Neurosci 14:580357. https://doi.org/10.3389/fnins.2020.580357
doi: 10.3389/fnins.2020.580357
pubmed: 33551717
Hsieh LS, Wen JH, Claycomb K, Huang Y, Harrsch FA, Naegele JR, Hyder F, Buchanan GF et al (2016) Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement. Nat Commun 7:11753. https://doi.org/10.1038/ncomms11753
doi: 10.1038/ncomms11753
pubmed: 27249187
pmcid: 4895394
Lim JS, Kim WI, Kang HC, Kim SH, Park AH, Park EK, Cho YW, Kim S et al (2015) Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med 21(4):395–400. https://doi.org/10.1038/nm.3824
doi: 10.1038/nm.3824
pubmed: 25799227
D'Gama AM, Poduri A (2021) Precision therapy for epilepsy related to brain malformations. Neurotherapeutics. https://doi.org/10.1007/s13311-021-01122-6
Theilmann W, Gericke B, Schidlitzki A, Muneeb Anjum SM, Borsdorf S, Harries T, Roberds SL, Aguiar DJ et al (2020) Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology 180:108297. https://doi.org/10.1016/j.neuropharm.2020.108297
doi: 10.1016/j.neuropharm.2020.108297
pubmed: 32890589
Talos DM, Sun H, Kosaras B, Joseph A, Folkerth RD, Poduri A, Madsen JR, Black PM et al (2012) Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. Ann Neurol 71(4):539–551. https://doi.org/10.1002/ana.22696
doi: 10.1002/ana.22696
pubmed: 22447678
pmcid: 3334406
Ruffolo G, Iyer A, Cifelli P, Roseti C, Muhlebner A, van Scheppingen J, Scholl T, Hainfellner JA et al (2016) Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions. Neurobiol Dis 95:93–101. https://doi.org/10.1016/j.nbd.2016.07.014
doi: 10.1016/j.nbd.2016.07.014
pubmed: 27425893
Cepeda C, Levinson S, Yazon VW, Barry J, Mathern GW, Fallah A, Vinters HV, Levine MS, Wu JY (2018) Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non-mTOR-mediated etiologies. Epilepsia Open 3(Suppl Suppl 2):180–190. https://doi.org/10.1002/epi4.12253
doi: 10.1002/epi4.12253
pubmed: 30564777
pmcid: 6293070
Ringstedt T, Linnarsson S, Wagner J, Lendahl U, Kokaia Z, Arenas E, Ernfors P, Ibáñez CF (1998) BDNF regulates reelin expression and Cajal-Retzius cell development in the cerebral cortex. Neuron 21(2):305–315. https://doi.org/10.1016/s0896-6273(00)80540-1
doi: 10.1016/s0896-6273(00)80540-1
pubmed: 9728912
Lizarraga SB, Ma L, Maguire AM, van Dyck LI, Wu Q, Ouyang Q, Kavanaugh BC, Nagda D et al (2021) Human neurons from Christianson syndrome iPSCs reveal mutation-specific responses to rescue strategies. Sci Transl Med 13(580). https://doi.org/10.1126/scitranslmed.aaw0682
Zheng DH, Guo W, Sun FJ, Xu GZ, Zang ZL, Shu HF, Yang H (2016) Expression of TRPC6 and BDNF in cortical lesions from patients with focal cortical dysplasia. J Neuropathol Exp Neurol 75(8):718–730. https://doi.org/10.1093/jnen/nlw044
doi: 10.1093/jnen/nlw044
pubmed: 27288906
pmcid: 4940447
Ku KM, Weir RK, Silverman JL, Berman RF, Bauman MD (2016) Behavioral phenotyping of juvenile Long-Evans and Sprague-Dawley rats: implications for preclinical models of autism spectrum disorders. PLoS One 11(6):e0158150. https://doi.org/10.1371/journal.pone.0158150
doi: 10.1371/journal.pone.0158150
pubmed: 27351457
pmcid: 4924796
Tkac I, Rao R, Georgieff MK, Gruetter R (2003) Developmental and regional changes in the neurochemical profile of the rat brain determined by in vivo 1H NMR spectroscopy. Magn Reson Med 50(1):24–32. https://doi.org/10.1002/mrm.10497
doi: 10.1002/mrm.10497
pubmed: 12815675
Ripps H, Shen W (2012) Review: taurine: a “very essential” amino acid. Mol Vis 18:2673–2686
pubmed: 23170060
pmcid: 3501277
Oja SS, Saransaari P (2013) Taurine and epilepsy. Epilepsy Res 104(3):187–194. https://doi.org/10.1016/j.eplepsyres.2013.01.010
doi: 10.1016/j.eplepsyres.2013.01.010
pubmed: 23410665
Rodrigo R, Felipo V (2007) Control of brain glutamine synthesis by NMDA receptors. Front Biosci 12:883–890. https://doi.org/10.2741/2110
doi: 10.2741/2110
pubmed: 17127345
Blüml S, Wisnowski JL, Nelson MD, Paquette L, Gilles FH, Kinney HC, Panigrahy A (2013) Metabolic maturation of the human brain from birth through adolescence: insights from in vivo magnetic resonance spectroscopy. Cereb Cortex 23(12):2944–2955. https://doi.org/10.1093/cercor/bhs283
doi: 10.1093/cercor/bhs283
pubmed: 22952278
Towner RA, Gulej R, Zalles M, Saunders D, Smith N, Lerner M, Morton KA, Richardson A (2021) Rapamycin restores brain vasculature, metabolism, and blood-brain barrier in an inflammaging model. Geroscience 43(2):563–578. https://doi.org/10.1007/s11357-021-00363-9
doi: 10.1007/s11357-021-00363-9
pubmed: 33846885
pmcid: 8110648
Morgan JJ, Kleven GA, Tulbert CD, Olson J, Horita DA, Ronca AE (2013) Longitudinal 1H MRS of rat forebrain from infancy to adulthood reveals adolescence as a distinctive phase of neurometabolite development. NMR Biomed 26(6):683–691. https://doi.org/10.1002/nbm.2913
doi: 10.1002/nbm.2913
pubmed: 23322706
pmcid: 3634877